02914nas a2200253 4500008004100000245012800041210006900169260001800238300001200256490000700268520208100275653002402356653003402380653003502414653002602449653002302475100001902498700002702517700002702544700001902571700001702590700001702607856003602624 2025 eng d00aEfficacy of Standardized Withania Somnifera as Neuro Agent in Tension-Type Headache: A Comparative Trial of Data in Transit0 aEfficacy of Standardized Withania Somnifera as Neuro Agent in Te cDecember 2025 a378-3850 v173 a

Background: To evaluate the role of withania somnifera as a neuro-psychiatric agent in the treatment of Tension-Type Headache (TTH), there is a need to substantiate the therapy using solid therapeutic evidence. Although using traditional medicine has a great potential, it is difficult to demonstrate the efficacy of a particular phytochemical composition regarding the frequency of and physiological stress markers of the chronic Tension-Type Headache in standardized research. Objective: The purpose of the study is to assess the therapeutic efficacy of a standardized Withania somnifera extract in reducing the frequency of and physiological stress markers of the chronic Tension-Type Headache. Methods: We used the study as a double-blind and randomized controlled trial (RCT). The subjects were randomly selected to be given a standardized extract of the root of W. somnifera, that has been titrated to contain 5 percent withanolides, or a placebo dose of 60 days. The paper ensured a rigorous "molecular chain of custody" with a batch of withanolides linked in clinical outcome reported where the mean frequency of headaches in the treatment group reduced by 42% (p [Less than] 0.005). Results: Clinical outcome showed that there was a significant decline in the frequency of headaches in the treatment group by 42% (p [Less than] 0.005). Moreover, the Ashwagandha group was showing a significant drop in salivary cortisol levels, which means that there was a decrease in the level of physiological stress response to chronic TTH. Conclusion: Standardized natural products should be integrated into clinical trials as it is the most beneficial to the development of sustainable pharmacognosy. This experiment can offer an unambiguous evidence base, a clear and reproducible basis of evidence regarding the use of Ashwagandha in the current neurological practice by showing the clear efficacy in reducing the frequency of Tension-Type Headaches and biological stress markers.

10aBiomarker Integrity10aPhytochemical Standardization10aSustainable Research Framework10aTension-Type Headache10aWithania somnifera1 aKumar, Ashwani1 aAngra, Prikshat, Kumar1 aAkula, Suresh, Chandra1 aSingh, Pritpal1 aSharma, Anuj1 aSharma, Anup uhttps://phcogj.com/article/2582